RxDoctor Payments Data

Louie Kostopoulos, MD

Interventional Cardiology · Milwaukee, WINPI 1356431001

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.5%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 51.8% of the total. 2025 is the largest year on record at $10,460, 2.8 times the $3,714 reported in 2019.

$25,694in general payments, 2019–2025

Across 171 payments — averaging $150.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Abiomed$5K
  • Penumbra, Inc.$2K
  • Abbott$2K
  • Boston Scientific$2K
  • W. L. Gore & Associates, Inc.$562
  • plus $1K from 9 others
$27,918in research payments, 2019–2025

Across 7 payments — averaging $3988.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Magenta Medical Inc$17K
  • EKOS Corporation$7K
  • Boston Scientific$4K
  • Abiomed$40

What the payments were for

  • Travel & lodging$14,52457%
  • Food & beverage$11,05843%
  • Gifts$1120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,694 in reported general payments places this provider in the 85th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$188,421
Medicare patients
748
Services billed
3,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$833,129
EliquisApixaban470$444,130
EntrestoSacubitril/Valsartan222$221,070
Repatha SureclickEvolocumab153$139,427
XareltoRivaroxaban96$120,771
BrilintaTicagrelor82$60,214
JardianceEmpagliflozin43$54,028
Praluent PenAlirocumab59$29,982
VascepaIcosapent Ethyl38$16,707
Metoprolol Succinate642$7,428
Atorvastatin Calcium732$6,331
ClopidogrelClopidogrel Bisulfate487$4,970
Potassium Chloride129$3,165
Midodrine Hcl30$2,993
Prasugrel Hcl43$2,942

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →